|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
US6238921B1
(en)
*
|
1998-03-26 |
2001-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human mdm2 expression
|
|
CA2328406A1
(en)
*
|
1998-05-14 |
1999-11-18 |
Hermann Wagner |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
|
AU5337499A
(en)
*
|
1998-08-03 |
2000-03-06 |
East Carolina University |
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
|
|
PT1832657E
(pt)
*
|
1998-09-09 |
2013-01-08 |
Genzyme Corp |
Metilação de vectores plasmídicos
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
|
IL140054A0
(en)
*
|
1999-04-06 |
2002-02-10 |
Univ East Carolina |
Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
|
|
US20040171566A1
(en)
*
|
1999-04-06 |
2004-09-02 |
Monia Brett P. |
Antisense modulation of p38 mitogen activated protein kinase expression
|
|
US6140124A
(en)
*
|
1999-04-06 |
2000-10-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of P38 mitogen activated protein kinase expression
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
JP5268214B2
(ja)
*
|
1999-08-13 |
2013-08-21 |
イデラ ファーマシューティカルズ インコーポレイテッド |
ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調
|
|
EP1496121A3
(en)
*
|
1999-08-13 |
2005-02-09 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
EP1229931A4
(en)
*
|
1999-10-07 |
2003-05-28 |
Corixa Corp |
FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
|
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
|
DE60131430T2
(de)
|
2000-01-14 |
2008-10-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
|
DE60143425D1
(de)
|
2000-02-23 |
2010-12-23 |
Smithkline Beecham Biolog |
Neue verbindungen
|
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US20040006036A1
(en)
*
|
2000-04-12 |
2004-01-08 |
Gmr, A Delaware Corporation |
Silencing transcription by methylation
|
|
ATE395923T1
(de)
|
2000-05-19 |
2008-06-15 |
Corixa Corp |
Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren
|
|
DE60139963D1
(de)
|
2000-06-20 |
2009-10-29 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
|
EP1961819A3
(en)
|
2000-06-28 |
2008-11-12 |
Corixa Corporation |
Composition and methods for the therapy and diagnosis of lung cancer
|
|
JP2004509970A
(ja)
*
|
2000-09-26 |
2004-04-02 |
ハイブリドン・インコーポレイテッド |
位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
|
|
AU2001297693A1
(en)
*
|
2000-12-08 |
2002-09-12 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
EP1515982A4
(en)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
|
US8114418B2
(en)
|
2001-06-21 |
2012-02-14 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—IV
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
|
PT1567641E
(pt)
|
2001-08-24 |
2012-08-21 |
Uvic Industry Partnerships Inc |
Proaerolisina contendo sequência de activação de proteases e métodos de uso para o tratamento do cancro da próstata
|
|
CN100392085C
(zh)
*
|
2001-09-20 |
2008-06-04 |
葛兰素集团有限公司 |
疫苗
|
|
WO2003027313A2
(en)
|
2001-09-24 |
2003-04-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
PT1456380E
(pt)
*
|
2001-11-02 |
2012-07-23 |
Giuliani Int Ltd |
Inibidores smad7 para o tratamento de doenças do snc
|
|
CA2860702C
(en)
|
2001-12-17 |
2019-02-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
JP2005526497A
(ja)
*
|
2002-02-04 |
2005-09-08 |
ビオミラ，インコーポレーテッド |
免疫刺激性、共有結合性脂質化オリゴヌクレオチド
|
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
|
AU2003263963A1
(en)
|
2002-08-01 |
2004-02-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
ES2556970T3
(es)
|
2003-01-06 |
2016-01-21 |
Corixa Corporation |
Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
|
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
|
EP1608403A2
(en)
*
|
2003-04-02 |
2005-12-28 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
AU2004275876B2
(en)
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
|
SG122973A1
(en)
*
|
2003-10-30 |
2006-06-29 |
Coley Pharm Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
|
CN1989439B
(zh)
|
2004-05-06 |
2010-12-29 |
美国政府健康及人类服务部 |
治疗葡萄膜炎的方法以及组合物
|
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
WO2006104890A2
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
|
KR20130110233A
(ko)
|
2005-04-29 |
2013-10-08 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
|
|
JP5220594B2
(ja)
|
2005-06-14 |
2013-06-26 |
プロトクス セラピューティックス インコーポレイティッド |
ポア形成修飾タンパク質を用いて良性前立腺肥大症を治療または予防する方法
|
|
KR101251707B1
(ko)
|
2006-09-27 |
2013-04-11 |
콜리 파마슈티칼 게엠베하 |
면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
|
|
BRPI0809926B8
(pt)
*
|
2007-04-04 |
2021-05-25 |
Infectious Disease Res Inst |
composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
|
|
US9452209B2
(en)
*
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
|
EP3061462B1
(en)
|
2007-07-02 |
2019-02-27 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
EP2224954B1
(en)
|
2007-11-07 |
2014-01-08 |
Celldex Therapeutics, Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
|
JP5711972B2
(ja)
|
2007-12-24 |
2015-05-07 |
アイディー バイオメディカル コーポレイション オブ ケベック |
組換えｒｓｖ抗原
|
|
EP2278979A4
(en)
|
2008-05-21 |
2012-09-26 |
Us Gov Health & Human Serv |
PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODEOXYNUCLEOTIDES
|
|
US20110268757A1
(en)
|
2008-12-03 |
2011-11-03 |
Institut Pasteur |
Use of phenol-soluble modulins for vaccine development
|
|
SG176807A1
(en)
|
2009-06-24 |
2012-01-30 |
Id Biomedical Corp Quebec |
Vaccine
|
|
PT2445526T
(pt)
|
2009-06-24 |
2016-08-16 |
Glaxosmithkline Biologicals Sa |
Antigénios de rsv recombinantes
|
|
PL3178490T3
(pl)
|
2009-07-15 |
2022-08-01 |
Glaxosmithkline Biologicals S.A. |
Kompozycje białka f rsv i sposoby ich wytwarzania
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
MX339621B
(es)
|
2010-04-13 |
2016-06-02 |
Celldex Therapeutics Inc * |
Anticuerpos que se unen a cd27 humano y uso de los mismos.
|
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
EA201390676A1
(ru)
|
2010-11-08 |
2013-11-29 |
Инфекшес Дизиз Рисерч Инститьют |
Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
|
ES2651143T3
(es)
|
2011-05-13 |
2018-01-24 |
Glaxosmithkline Biologicals Sa |
Antígenos de F de prefusión del VRS
|
|
AU2012273153A1
(en)
|
2011-06-21 |
2013-05-02 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
|
PT2879701T
(pt)
|
2012-08-03 |
2024-02-12 |
Access To Advanced Health Inst |
Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
WO2014024026A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
|
CN105473604B
(zh)
|
2013-03-13 |
2021-01-22 |
美国政府(由卫生和人类服务部的部长所代表) |
融合前rsv f蛋白和其用途
|
|
US10058603B2
(en)
|
2013-03-15 |
2018-08-28 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
KR20160040290A
(ko)
|
2013-08-05 |
2016-04-12 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
조합 면역원성 조성물
|
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
|
AU2015365583B2
(en)
|
2014-12-19 |
2021-10-28 |
Regenesance B.V. |
Antibodies that bind human C6 and uses thereof
|
|
JP6647315B2
(ja)
|
2015-01-09 |
2020-02-14 |
イーチュービクス コーポレイション |
組み合わせ免疫療法のための方法および組成物
|
|
US10813993B2
(en)
|
2015-03-03 |
2020-10-27 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
EP3302544A4
(en)
|
2015-05-26 |
2019-01-09 |
Ohio State Innovation Foundation |
NANOPARTICLE-BASED VACCINE STRATEGY AGAINST SWINE INFLUENZA VIRUS
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
|
KR102414558B1
(ko)
|
2016-04-18 |
2022-06-29 |
셀덱스 쎄라퓨틱스, 인크. |
인간 cd40에 결합하는 효능성 항체 및 이의 용도
|
|
EP3458088A2
(en)
|
2016-05-21 |
2019-03-27 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
|
EP3463440A4
(en)
|
2016-05-27 |
2020-04-15 |
Etubics Corporation |
NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
|
|
MX2019003035A
(es)
|
2016-09-16 |
2019-09-13 |
Infectious Disease Res Inst |
Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
|
|
EP3554538A2
(en)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
|
US11141377B2
(en)
|
2017-06-15 |
2021-10-12 |
Infectious Disease Research Institute |
Nanostructured lipid carriers and stable emulsions and uses thereof
|
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
|
CA3081581A1
(en)
|
2017-11-03 |
2019-05-09 |
Takeda Vaccines, Inc. |
Method for inactivating zika virus and for determining the completeness of inactivation
|
|
EP3743102A1
(en)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
EP3768702A4
(en)
|
2018-03-22 |
2022-05-04 |
Board of Regents, The University of Texas System |
SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) THERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER
|
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
WO2022051022A1
(en)
|
2020-09-04 |
2022-03-10 |
Infectious Disease Research Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
WO2022217019A1
(en)
|
2021-04-09 |
2022-10-13 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
|
US20250082745A1
(en)
|
2021-12-13 |
2025-03-13 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
|
EP4583841A1
(en)
|
2022-09-09 |
2025-07-16 |
Access to Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
|
KR20250167153A
(ko)
|
2023-03-03 |
2025-11-28 |
셀덱스 쎄라퓨틱스, 인크. |
항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
|